XML 81 R50.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Segments (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2019
Summary of Segment Profit |
a. | Segment information:
|  | Year ended December 31, |
|  | 2019 |
|  | North America |  |  | Europe |  |  | International Markets * |
|  | (U.S. $ in millions) |
Revenues |  | $ | 8,542 |  |  | $ | 4,795 |  |  | $ | 2,246 |
Gross profit |  |  | 4,350 |  |  |  | 2,704 |  |  |  | 1,167 |
R&D expenses |  |  | 652 |  |  |  | 262 |  |  |  | 88 |
S&M expenses |  |  | 1,021 |  |  |  | 890 |  |  |  | 481 |
G&A expenses |  |  | 439 |  |  |  | 239 |  |  |  | 138 |
Other income |  |  | (14 | ) |  |  | (5 | ) |  |  | (3 | )
Segment profit |  | $ | 2,252 |  |  | $ | 1,318 |  |  | $ | 464 |
|  | Year ended December 31, |
|  | 2018 |
|  | North America |  |  | Europe |  |  | International Markets * |
|  | (U.S. $ in millions) |
Revenues |  | $ | 9,297 |  |  | $ | 5,186 |  |  | $ | 2,422 |
Gross profit |  |  | 4,979 |  |  |  | 2,884 |  |  |  | 1,254 |
R&D expenses |  |  | 713 |  |  |  | 283 |  |  |  | 96 |
S&M expenses |  |  | 1,154 |  |  |  | 1,003 |  |  |  | 518 |
G&A expenses |  |  | 484 |  |  |  | 325 |  |  |  | 153 |
Other income |  |  | (209 | ) |  |  | — |  |  |  | (11 | )
Segment profit |  | $ | 2,837 |  |  | $ | 1,273 |  |  | $ | 498 |
|  | Year ended December 31, |
|  | 2017 |
|  | North America |  |  | Europe |  |  | International Markets* |
|  | (U.S. $ in millions) |
Revenues |  | $ | 12,141 |  |  | $ | 5,466 |  |  | $ | 2,863 |
Gross profit |  |  | 7,322 |  |  |  | 2,887 |  |  |  | 1,433 |
R&D expenses |  |  | 969 |  |  |  | 390 |  |  |  | 154 |
S&M expenses |  |  | 1,288 |  |  |  | 1,130 |  |  |  | 672 |
G&A expenses |  |  | 533 |  |  |  | 354 |  |  |  | 189 |
Other income |  |  | (92 | ) |  |  | (16 | ) |  |  | (8 | )
Segment profit |  | $ | 4,624 |  |  | $ | 1,029 |  |  | $ | 426 |
* | The data presented for prior periods have been revised to reflect a revision in the presentation of net revenues and cost of sales in the consolidated financial statements. See note 1b.
Schedule Of Consolidated Income Before Income Tax |
|  | Year ended |
|  | December 31, |
|  | 2019 |  |  | 2018 |  |  | 2017 |
|  | (U.S. $ in millions) |
North America profit |  | $ | 2,252 |  |  | $ | 2,837 |  |  | $ | 4,624 |
Europe profit |  |  | 1,318 |  |  |  | 1,273 |  |  |  | 1,029 |
International Markets profit |  |  | 464 |  |  |  | 498 |  |  |  | 426 |
Total reportable segments profit |  |  | 4,034 |  |  |  | 4,608 |  |  |  | 6,079 |
Profit (loss) of other activities |  |  | 108 |  |  |  | 115 |  |  |  | (6 | )
Total segments profit |  |  | 4,142 |  |  |  | 4,723 |  |  |  | 6,073 |
Amounts not allocated to segments: |  |  |  |  |  |  |  |  |  |  |  |
Amortization |  |  | 1,113 |  |  |  | 1,166 |  |  |  | 1,444 |
Other asset impairments, restructuring and other items |  |  | 423 |  |  |  | 987 |  |  |  | 1,836 |
Goodwill impairment |  |  | — |  |  |  | 3,027 |  |  |  | 17,100 |
Intangible asset impairments |  |  | 1,639 |  |  |  | 1,991 |  |  |  | 3,238 |
Gain on divestitures, net of divestitures related costs |  |  | (50 | ) |  |  | (66 | ) |  |  | (1,083 | )
Inve nto r y St ep — up |  |  | — |  |  |  | — |  |  |  | 67 |
Other R&D expenses |  |  | (15 | ) |  |  | 83 |  |  |  | 221 |
Costs related to regulatory actions taken in facilities |  |  | 45 |  |  |  | 14 |  |  |  | 47 |
Legal settlements and loss contingencies |  |  | 1,178 |  |  |  | (1,208 | ) |  |  | 500 |
Other unallocated amounts |  |  | 252 |  |  |  | 366 |  |  |  | 187 |
Consolidated operating income (loss) |  |  | (443 | ) |  |  | (1,637 | ) |  |  | (17,484 | )
Financial expenses, net |  |  | 822 |  |  |  | 959 |  |  |  | 895 |
Consolidated income (loss) before income taxes |  | $ | (1,265 | ) |  | $ | (2,596 | ) |  | $ | (18,379 | )
Schedule of Net Sales by Product Line | North America segment:
|  | Year ended December 31, |
|  | 2019 |  |  | 2018 |  |  | 2017 |
|  | (U.S. $ in millions) |
Generic products |  | $ | 3,963 |  |  | $ | 4,056 |  |  | $ | 5,203 |
COPAXONE |  |  | 1,017 |  |  |  | 1,759 |  |  |  | 3,116 |
BENDEKA/TREANDA |  |  | 496 |  |  |  | 642 |  |  |  | 656 |
ProAir* |  |  | 274 |  |  |  | 397 |  |  |  | 501 |
QVAR |  |  | 250 |  |  |  | 182 |  |  |  | 313 |
AJOVY |  |  | 93 |  |  |  | 3 |  |  |  | — |
AUSTEDO |  |  | 412 |  |  |  | 204 |  |  |  | 24 |
Anda |  |  | 1,492 |  |  |  | 1,347 |  |  |  | 1,153 |
Other |  |  | 546 |  |  |  | 708 |  |  |  | 1,175 |
Total |  | $ | 8,542 |  |  | $ | 9,297 |  |  | $ | 12,141 |
* | Does not include revenues from the ProAir authorized generic, which are included under generic products.
Europe segment:
|  | Year ended December 31, |
|  | 2019 |  |  | 2018 |  |  |  | 2017 |
|  | (U.S. $ in millions) |
Generic products |  | $ | 3,470 |  |  | $ | 3,593 |  |  | $ | 3,471 |
COPAXONE |  |  | 432 |  |  |  | 535 |  |  |  | 595 |
Respiratory products |  |  | 354 |  |  |  | 402 |  |  |  | 368 |
Other |  |  | 539 |  |  |  | 656 |  |  |  | 1,033 |
Total |  | $ | 4,795 |  |  | $ | 5,186 |  |  | $ | 5,466 |
International Markets segme n t:
|  | Year ended December 31, |
|  | 2019 |  |  | 2018 |  |  | 2017 |
|  | (U.S. $ in millions) |
Generic products |  | $ | 1,893 |  |  | $ | 2,022 |  |  | $ | 2,370 |
COPAXONE |  |  | 63 |  |  |  | 72 |  |  |  | 91 |
Distributio n |  |  | 20 |  |  |  | 19 |  |  |  | 17 |
Other |  |  | 271 |  |  |  | 309 |  |  |  | 385 |
Total |  | $ | 2,246 |  |  | $ | 2,422 |  |  | $ | 2,863 |
* | The data presented for prior periods have been revised to reflect a revision in the presentation of net revenues and cost of sales in the consolidated financial statements. See note 1b.
Schedule of Sales Percentage by Therapeutic Category | The following table represents the percentage of consolidated third party net sales to Teva’s major customers during the years ended December 31, 2019, 2018 and 2017.
|  | Percentage of Third Party Net Sales |
|  | 2019 |  |  | 2018 |  |  | 2017 |
McKesson Corporation |  |  | 13 | % |  |  | 12 | % |  |  | 16 | %
AmerisourceBergen Corporation |  |  | 12 | % |  |  | 14 | % |  |  | 15 | %
Schedule of Property, Plant and Equipment by Geographic Location |
d. | Property, plant and equipment—by geographical location were as follows:
|  | December 31, |
|  | 2019 |  |  | 2018 |
|  | (U.S. $ in millions) |
Israel |  | $ | 1,670 |  |  | $ | 1,987 |
United States |  |  | 864 |  |  |  | 950 |
Croatia |  |  | 517 |  |  |  | 538 |
Germany |  |  | 665 |  |  |  | 518 |
Czech republic |  |  | 343 |  |  |  | 352 |
Hungary |  |  | 330 |  |  |  | 343 |
Japan |  |  | 177 |  |  |  | 188 |
Other |  |  | 1,870 |  |  |  | 1,992 |
Total property, plant and equipment |  | $ | 6,436 |  |  | $ | 6,868 |

X
- Definition A schedule indicating where long-lived tangible assets are located. + References No definition available. + Details
Name: | teva_PropertyPlantAndEquipmentByGeographicAreaTableTextBlock
Namespace Prefix: | teva_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition A schedule of net sales by therapeutic category, stated as a percentage of total sales. + References No definition available. + Details
Name: | teva_SalesPercentageByTherapeuticCategoryTableTextBlock
Namespace Prefix: | teva_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Schedule of consolidated income before income tax. + References No definition available. + Details
Name: | teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock
Namespace Prefix: | teva_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8924-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599 + Details
Name: | us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599 + Details
Name: | us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration